Kornimate/medical-research-clean huggingface dataset:
evaluation of the efficacy of radiofrequency in the treatment of renal tumors

Conditions: Renal Cell Carcinoma

Summary: multi-institutional registry on a cohort of 310 patients with biopsy-proven renal cell carcinoma treated by radiofrequency ablation. all patients will be included consecutively and retrospectively in all centers to obtain the required number of patient followed during 5 years.

radiofrequency ablation (rfa) of renal cell carcinoma (rcc) is actually used in elderly patients with small renal tumors (diameter ≤ 4 cm) and presenting a high risk of surgery (due to co-morbidity) and/or reduced renal function. rfa is a minimally invasive technique, considered as an alternative to surgery to limit morbidity and to preserve kidney function. the technique is well known and has proven his efficacy for the treatment of small tumors. an enlargement of the indications of rfa to patient without contra-indication to surgery will depend on the efficacy of the technique. the main objective of the study is to evaluate the local efficacy of the ablation based on the technical success, and on the evaluation of local cancer recurrence over 5 years.

Eligibility criteria:
inclusion criteria: * patient treated with percutaneous rfa * patient with diagnosis of renal masses with a maximum of 3 masses treated during the ablation * the diameter of the tumor must be ≤ 40 mm, characterized by ct-scan or mri * the histology of the tumor must be biopsy-proven or the patient must have previous surgical ablation of renal tumor (ipsi or contralateral) exclusion criteria: * patient treated by surgery or laparoscopy * benign tumors * no histological diagnosis (no biopsy or no previous treated renal carcinoma) * patient having secondary malignant sites, ganglions or visceral metastatic cells or endo-venous extend at the time of rfa * patient having a diagnosis of primary or secondary extra-renal tumor location and not into remission * patients treated with antiangiogenic drugs during the 6 months prior rfa.

Keywords: radiofrequency ablation complications
fecal microbiota and monocyte trained immunity in chd patients with different hscrp

Conditions: Coronary Heart Disease; Unstable Angina

Summary: this single-center study enrolled patients aged 35-75 years who were diagnosed with unstable angina (ua), and had at least one of the three major coronary arteries with a ≥ 50% reduction in lumen diameter by angiographic visual estimation. patients were all recruited at the department of cardiology, union hospital, wuhan, hubei province, china. feces and blood samples were collected on admission were used promptly for ex vivo studies.

this single-center study enrolled patients aged 35-75 years who were diagnosed with unstable angina (ua), and had at least one of the three major coronary arteries with a ≥ 50% reduction in lumen diameter by angiographic visual estimation. patients were all recruited at the department of cardiology, union hospital, wuhan, hubei province, china. exclusion criteria included acute myocardial infarction, prior myocardial infarction, malignancies, auto-immune or auto-inflammatory diseases, or ongoing infection. feces and blood samples were collected on admission were used promptly for ex vivo studies. the aim of the study is to investigate whether the fecal microbiota and peripheral blood monocytes in patients with coronary heart disease at different levels of inflammation are associated with the level of inflammation.

Eligibility criteria:
inclusion criteria: 1. age \>35 and \<75 years 2. admitted for ua and had at least one of the three major coronary arteries with ≥50% reduction in lumen diameter by angiographic visual estimation 3. informed consent obtained exclusion criteria: 1. prior myocardial infarction 2. left ventricular ejection fraction ≤ 40% on echocardiography 3. have a history of malignancies, auto-immune, auto-inflammatory disease or on immunomodulatory medication 4. ongoing acute, chronic, or concurrent infectious disease 5. surgery 3 months before sample collection 6. immunization with a vaccine within 4 weeks before sample collection 7. pregnancy, or breast feeding 8. history of primary or secondary immunodeficiency 9. renal failure with estimated glomerular filtration rate (egfr) \< 60 ml/min/1.73m2 10. active liver disease with alanine aminotransferase (alt \>80 u/l) or aspartate aminotransferase (ast \> 80 u/l) 11. history of chronic obstructive pulmonary disease (copd) 12. refuse to provide written consent 13. any other circumstances in which the investigator judges that the patient is not suitable
pilates and pnf methods induces similar strength gains

Conditions: Sarcopenia

Summary: to compare the influence of a training program with pilates and pnf methods to elderly women on the strength gains and motor control during voluntary contractions

sixty healthy elderly women were randomly divided into 3 groups: pilates group (pg), pnf group (pnfg) and control group (cg). pilates and pnf groups underwent one-month (three times per week) training program with pilates and pnf methods, respectively. cg received no intervention along the one month. the maximal isometric force from knee extension and flexion, as well as the emg signal from quadriceps and biceps femoris were recorded before and after the one-month intervention period. a two-way analysis of variance (3 groups x 2 measures) was used to compare the results from emg signal, isometric force and force variability and force spectrum. a one-month training program with pilates and pnf methods induces similar strength gains from knee flexors and extensors, without differences between methods, but pg exhibited greater low gamma drive (i.e., 30-60 hz band) after the training period. both pilates and pnf methods were efficient to improve the muscle strength, but with different neuromuscular adaptations in elderly women. these results give support to the recommendation these methods to older age groups, since the increment of lower limb muscle strength is important for gait, postural stability and performance of daily life activities of this population.

Eligibility criteria:
inclusion criteria: * all the subjects were between 60 an 80 years old, sedentary and healthy exclusion criteria: * subjects were excluded from the study if they presented any orthopedic, neurological, cardiac, vestibular, visual, or psychiatric impairment which would not allow them to perform all the tasks in the study

Keywords: electromyography aged muscle strength wavelet analysis pilates proprioceptive neuromuscular facilitation
hs abscesses: i&d vs punch debridement

Conditions: Hidradenitis Suppurativa (Acne Inversa)

Summary: this randomized-control trial is designed to determine the recurrence rate of hs abscesses following drainage via two methods: i\&d with a linear incision and pd with an 8mm punch biopsy. in this context, recurrence is a newly described hs abscess adjacent to or within the previously operated area, for which a second intervention is deemed necessary. we hypothesize that pd may yield a more favorable recurrence rate. in addition to comparing recurrence rates, this randomized-control trial will also evaluate postprocedural pain, the occurrence and type of complications, and patients' quality of life associated with both procedures. these additional factors are crucial in assessing the overall effectiveness and patient satisfaction associated with each method, further informing the potential establishment of pd as the new gold standard for draining small, painful, acute hs abscesses.


Eligibility criteria:
inclusion criteria: * diagnosed with hs * has an abscess requiring drainage with a maximum diameter of 5 centimeters. * age 16 years or older * willing and able to provide informed consent exclusion criteria: * has other conditions that could interfere with the study, as estimated by physician * unable to comply with follow-up visits * allergic to lidocaine and/or adrenaline.

Keywords: punch biopsy tool drainage abscess i&amp;amp;d
a study to evaluate the effect of mechanical ventilation on the inferior vena cava collapsibility index

Conditions: Respiratory Failure

Summary: previous research has shown that the inferior vena cava collapsibility index (ivcci) can be used to assess volume status. one limitation of the previous work is that changes in intra-thoracic pressure can influence this measurement, and the magnitude of this effect has never been described. the investigators aim is to correlate the degree of change in ivcci with the set degree of change in intra-thoracic pressure in a heterogeneous population of critically ill patients.

initially eligible patients will be those admitted to the osu micu and 8icu within the prior 48 hours. these patients will be screened for predetermined exclusion criteria. eligible patients will have their ivcci measured and baseline peak and plateau pressures noted. for those patients meeting a second set of criteria, a common ventilator maneuver will be preformed. the positive end-expiratory pressure will be increased by 5-10 cm/h20 pressure. this procedure will be aborted if any safety criteria are exceeded. during the interval, the ivcci will be re-measured, the ventilator settings will be recorded, and the ventilator will be return to the initial settings. since changes of these same magnitude are made daily in clinical practice, the risks to the patients in this study will be minimal and no more than that experienced in the course of usual care.

Eligibility criteria:
inclusion criteria: 1. age\>17 years 2. current use of mechanical ventilation through an endotracheal tube. 3. admitted to icu within last 48 hours exclusion criteria: 1. severe copd by history (documented fev1\<50% predicted or ct evidence of emphysema) 2. current suspected asthma exacerbation 3. profound hypoxia defined as a fio2 requirement \>90% or a peep \>10 mmhg 4. patient-ventilator desynchrony or active agitation 5. unstable o2 requirement as determined by the primary clinical team. 6. prisoners 7. bedside clinician refusal (physician or treating nurse). exclusion criteria for ventilator changes: 1. cardiovascular instability (any increase in rate of vasopressors or i.v. fluid bolus for hypotension within the last four hours) 2. current peep requirements of \>15cmh2o 3. current spo2 of \<88%.
to compare the efficacy and safety of tripterygium (tw) versus aza in the maintenance therapy for lupus nephritis

Conditions: Lupus Nephritis

Summary: the purpose of this study is to: * to access the efficacy of tw compared to aza in the maintenance therapy for lupus nephritis * to investigate the safety and tolerability of tw versus aza in the maintenance therapy for lupus nephritis

tripterygium (tw) is a chinese traditional patent drugs in treating chronic glomerulonephritis. it has been used to treat lupus nephritis for many years with less side effects. we compare the efficacy and safety of tw vs aza in the maintenance therapy of lupus nephritis.

Eligibility criteria:
inclusion criteria: 1. patients who signed written informed consent form; 2. sle patient, aged between 18-60 years, female or male; 3. patients diagnosed lupus nephritis according to isn/rps 2003 classification criteria, class ⅲ, ⅳ,ⅳ+ⅴ, ⅲ+ⅴ or ⅴ ln by renal biopsy; 4. all patients received induction therapy for 6-12 months, including mmf, ctx, fk506 or multi-target therapy; 5. when recruited in the study, patients received partial remission or complete remission for 3 months; * complete remission: proteinuria \ 35 g/l, elevated scr \< 0.3 mg/dl, no extra-renal complications; * partial remission: proteinuria \ 35 g/l, elevated scr \<0.3 mg/dl, no extra-renal complications. exclusion criteria: 1. patients who didn't sign written informed consent form or could not obey the protocol; 2. patients who didn't received the cr or pr criterion; 3. patients who have impaired liver function, with alt/gpt or ast/got twice more than the normal upper limit; 4. wbc \< 3000/mm3 in peripheral blood; 5. patients with abnormal of central nervous system.
a study of gt267-004 versus vancomycin and gt267-004 versus metronidazole in patients with c.difficile - associated diarrhea

Conditions: Clostridium Enterocolitis; Pseudomembranous Colitis

Summary: approximately 520 patients will be entered into this study taking place throughout the us and canada. this study aims to determine if an investigational drug is safe and effective for treating symptoms of c. difficile-associated diarrhea (cdad) and lowering the risk of repeat episodes of cdad. the investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. all study related care is provided including doctor visits, physical exams, laboratory tests and study medication. total length of participation is approximately 6 weeks.


Eligibility criteria:
inclusion criteria: * 18 years of age * the presence of cdad at the time of enrollment with no other likely etiology for the diarrhea * less than or equal to 48 hours of treatment with metronidazole, vancomycin or other antibacterial therapy specific for cdad * baseline serum potassium \> 3.0 mmol (meq)/l * patient considered sufficiently stable clinically to likely complete a 6 week study period

Keywords: clostridium enterocolitis pseudomembranous colitis clostridium difficile-associated diarrhea c. difficile cdad
ives for treatment of uui and oab

Conditions: Urinary Bladder, Overactive; Urinary Incontinence, Urge

Summary: the pilot study is intended to show the efficacy of intravesical electrical stimulation in treating overactive bladder with or without frequency and/or urgency urinary incontinence.

the emed technologies detrusettm intravesical electrical stimulation (ives) catheter is indicated for use with the emed detrusantm 500 electrical generator for the treatment of overactive bladder and urge urinary incontinence (ui) in women who are not satisfied with or cannot tolerate other conservative treatments. emed is interested in conducting a prospective randomized multi-center study of ives therapy vs conventional ui treatments. in order to gain sufficient knowledge of the treatment effect and variability of ives therapy to power an rct, a pilot study will be initially conducted. the pilot study is intended to show the efficacy of ives in treating overactive bladder with or without frequency and/or urgency urinary incontinence with safety profile of ives being no worse than with standard urological catheters. a primary endpoint at 3 months showing reduction in incontinence events via a 7-level patient global impression of improvement will be established. secondary endpoints will include pci for subsets of symptoms, 3 day voiding diary, and patient satisfaction questionnaires. follow up at end of therapy and 3 months from the first therapy session will be conducted. 6-month, 9-month, and 12-month follow up can be conducted to establish durability of ives therapy if it is found to be effective at 3 months after the first treatment

Eligibility criteria:
inclusion criteria: * female * 18-90 years old * urinary urge incontinence or overactive bladder * prior trial of medical treatment for uui or oab exclusion criteria: * pelvic organ prolapse greater than stage 1 * multiple sclerosis * parkinson's disease * spinal cord injury * long-term dm type i * prior surgeries that may affect innervation of the detrusor nerves or the spinal cord * pregnancy * pacemaker/defibrillator * pvr \>150ml * dementia * stress urinary incontinence * intravesical botox injection within 1 year, ptns within 6 months, or medical treatment for oab within 3 weeks; bulking agent injection within 6 months
mindfulness-based stress reduction (mbsr) for reduction of chronic pain and drug therapie

Conditions: Chronic Pain

Summary: mindfulness-based cognitive therapy (mbct) combines ideas of traditional cognitive therapies with meditative practices aimed at cultivating mindfulness. mindfulness-based stress reduction (mbsr) is considered one of the original mindfulness-based interventions. it has been modified to be offered virtually,which has been useful throughout the covid pandemic, and more importantly, has served to inform other mindfulness approaches, such as trauma-focused therapy. the investigators want to assess the efficacy of mbsr in patients with chronic pain undergoing drug treatment.

mindfulness helps develop the ability to observe and detach from our mental, sensory, and emotional states, and thus increases our awareness and ability to manage emotions. in the experimental arm, some have been foreseen group sessions, in which a maximum of ten people participate on the mindfulness-based stress reduction (mbsr). the protocol provides for eight meetings (one and a half or two hours each) on a monthly basis, for a total duration, therefore, of twelve months.

Eligibility criteria:
inclusion criteria: * patients being treated for chronic pain * patients with chronic pain in pharmacological therapy exclusion criteria: * patients with chronic pain not in pharmacological therapy * patients without chronic pain
training given to caregivers of stroke home care patients.

Conditions: Stroke

Summary: although stroke home care patients receive various treatments, they generally continue their lives as semi-dependent or fully dependent. considering that stroke patients are especially elderly individuals, it is seen that they receive home health services and need a caregiver. the caregiver feels themselves under a heavy burden due to the lack of knowledge and insufficient experience. in addition, the lack of social support levels and the lack of training in patient care cause negative effects on patient outcomes.

the research will be carried out face-to-face with 70 stroke patients who receive health care from the home health services unit of a state hospital and 70 individuals who care for these patients between july 2023 and december 2023. this study is a single-sample study with its own control group. during the implementation phase of the research, home visits will be made to the patients and training based on the precede-proceed model will be given to the individuals who care for the patients in the meeting room of the hospital where the research will be conducted. the collection of research data will take place in three stages. in the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. in the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. after the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. the third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers. in the study, data will be collected using the individual caregiver personal information form, the caregiver response rating scale and the multidimensional perceived social support scale, and the patient personal information form for the patients. statistical significance level will be accepted as p\<0.05.

Eligibility criteria:
inclusion criteria: * individuals who care for semi-dependent or fully dependent stroke home care patients who agree to participate in the study, * no communication problems, * do not have any psychiatric disorders that will reduce the ability to comprehend and understand, * caregivers over the age of 18. * semi-dependent or fully dependent stroke home care patients, * adult patients, * patients whose legal guardians or who have agreed to participate in the research themselves, exclusion criteria: * the refusal of caregivers or patients to participate in the study, * the caregiver ceases to provide care or the patient dies during the research,

Keywords: stroke home care services caregivers social support patient-relevant outcome
pillcam colon capsule 2® (pcc2) in the setting of colorectal cancer screening program

Conditions: Colon Cancer

Summary: in this study the investigators evaluate the sensitivity of pcc2 (pillcam colon capsule 2 (r)) in identifying significant polyps in a crc (colo recatal cancer) screening program (primary outcome measure). each enrolled patient underwent three procedures: colon capsule endoscopy, ct-colonography and optical colonoscopy. in this study the reference standard is represented by the segmental unblinded colonoscopy (the unblinding is based on results of both capsule endoscopy and ct colonography) the investigators also evaluated the tolerability of pcc2 as compared to optical colonoscopy (oc) and ct-colonography (ctc).

asymptomatic average risk subjects with positive ifobt (immunochemical fecal occult blood test), participating the regional screening program, were offered to undergo pcc2 (pillcam colon capsule 2 (r)) followed, 21 days later, by ctc and oc performed on the same day. the number, size and location of significant polyps (\>6mm) identified by each procedure were compared with the reference standard (rs), which was represented by the segmental unblinded colonoscopy. the unblinding was based on the integration of ctc and pcc2 results. for the ppc2 the quality of the bowel preparation (adequate/inadequate) and the completeness of the examination (capsule excreted still working or visualization of the anal verge) were also reported. in order to evaluate the tolerability, each subject was asked to identify, among the 3 procedures performed, which was the less tolerated one and which one he would be willing to repeat.

Eligibility criteria:
inclusion criteria: * asymptomatic average risk subjects, participating the regional colon cancer screening program, with positive ifobt referred for colonoscopy exclusion criteria: * presence of obstructive symptoms * swallowing disorders * presence of cardiac pacemaker
prehabilitation prior to surgery for kidney tumors

Conditions: Renal Cancer; Renal Cell Cancer; Kidney Cancers; Stage I Renal Cell Cancer; Prehabilitation; Elderly (People Aged 65 or More)

Summary: the goal of this clinical trial is to examine if one month of general health optimization before surgery for kidney tumors can help participants recover more quickly from surgery. the optimization process is called prehabiliation, and will last one month. it consists of 1. a comprehensive health assessment 2. assisted smoking cessation 3. a home exercise program. the investigators will compare an intervention group receiving one month of prehabilitation with a control group receiving the standard of care. some of the main questions the investigators want to answer are * are participants in the intervention group more satisfied with their quality of recovery after surgery? * do participants in the intervention group maintain more of their physical abilites compared to the control group?


Eligibility criteria:
inclusion criteria: * 65 years or older * ct1 kidney tumor, scheduled for either partial or radical nephrectomy. * clinical frailty scale 3-6 exclusion criteria: * it is determined by an attending physician, or at a multi-disciplinary team-conference, that a 2-4 week postponement of surgery will not be beneficial for the participant. * participant does not understand danish og english

Keywords: prehabilitation quality of life kidney tumor renal cell tumor renal cell cancer kidney cancer quality of recovery elderly